This significant effect was derived by the use of fibrates ( RR 0.80 , 95 % CI 0.73–0.87 , P < 0.001 , I2 = 22 % ) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol .
Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints .
Conclusion The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality , stroke or all-cause mortality .
The beneficial effect on myocardial infa rct ion was lost when drugs were used with statin therapy
Background The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain .
Design We conducted a meta- analysis to investigate the effects of high-density lipoprotein cholesterol modifiers ( niacin , fibrates and cholesteryl ester transfer protein inhibitors ) on cardiovascular outcomes .
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.
The Cholesterol-Lowering Atherosclerosis Study ( CLAS ) was a r and omized , placebo-controlled , angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery . During two years of treatment there was a 26 % reduction in total plasma cholesterol , a 43 % reduction in low-density lipoprotein cholesterol , plus a simultaneous 37 % elevation of high-density lipoprotein cholesterol . This result ed in a significant reduction in the average number of lesions per subject that progressed ( P less than .03 ) and the percentage of subjects with new atheroma formation ( P less than .03 ) in native coronary arteries . Also , the percentage of subjects with new lesions ( P less than .04 ) or any adverse change in bypass grafts ( P less than .03 ) was significantly reduced . Deterioration in overall coronary status was significantly less in drug-treated subjects than placebo-treated subjects ( P less than .001 ) . Atherosclerosis regression , as indicated by perceptible improvement in overall coronary status , occurred in 16.2 % of colestipol-niacin treated vs 2.4 % placebo treated ( P = .002 )
This significant effect was derived by the use of fibrates ( RR 0.80 , 95 % CI 0.73–0.87 , P < 0.001 , I2 = 22 % ) and meta-regression analysis showed that this benefit was consistent with an absolute reduction in low-density lipoprotein cholesterol .
Meta-regression analyses failed to demonstrate a significant association of pharmacologically increased high-density lipoprotein cholesterol with key endpoints .
Conclusion The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality , stroke or all-cause mortality .
The beneficial effect on myocardial infa rct ion was lost when drugs were used with statin therapy
Background The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain .
Design We conducted a meta- analysis to investigate the effects of high-density lipoprotein cholesterol modifiers ( niacin , fibrates and cholesteryl ester transfer protein inhibitors ) on cardiovascular outcomes .